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Analysis of treatments used for individuals with Rett Syndrome who experience seizures
Harshita Nangunuri, Mentor: Professor Mary Boyes

Re1	
  Syndrome	
  

Epilep-c	
  Seizures	
  

Rett Syndrome (RTT) is a neurodevelopmental
disorder solely affecting females, and is caused by
genetic mutations in the methyl CpG binding protein
2 (MeCP2) gene. The MeCP2 gene produces the
MeCP2 protein, which has many diverse functions
including regulating the brain-derived neurotrophic
factor (BDNF) gene, which produces the BDNF
protein. Individuals with RTT have mutated MeCP2
genes, which results in low levels of MeCP2 protein
and BNDF protein.

Seizures are of a major concern for individuals with
RTT because they are fairly common and make life
much more difficult for these females. A female with
RTT has a 5-38% chance of developing epilepsy
and experiencing seizures as opposed to a 1-2%
chance in regular individuals. Some individuals
experience seizures in childhood, some in puberty
and some others well into adulthood. Thus seizures
can occur at any age, but the frequency of seizures
has been found to decrease significantly after the
age of twenty.

	
  
	
  

Regardless of these genetic mutations, individuals
with RTT develop normally until about six to eight
months of age. After this developmental window,
neurological differences become present which are
followed by phenotypic differences during which
motor skills, language skills and social skills are
impaired. In addition to these impairments,
individuals with RTT also experience other
symptoms such as breathing problems, sleep apnea
and seizures. Seizures are a common symptom
associated with RTT, as up to eighty percent of
individuals with RTT experience seizures.

Conclusion	
  
The use of AEDs is very common for females with
RTT who experience seizures. However, due to the
number of side effects associated with AEDs, they
are not readily available or desirable for all females
with RTT. Focusing research on treatments that will
halt or prevent the seizures from occurring rather
than treating the seizures as they appear will prove
to be more beneficial. Two such treatments in
consideration are increasing the amount of the
BDNF protein as well as increasing the MeCP2
protein present in the brain. Previous research in
mice has shown that increasing the levels of these
two proteins alleviates RTT-like symptoms.
However, additional research must be done in order
to implement these treatments effectively on a
widespread scale. These treatments also have the
potential to be administered during the
developmental window in which neurological
changes are present but phenotypic changes
associated with RTT are not. Treating females with
RTT who also experience seizures during this
developmental window can potentially halt
symptoms from appearing or help curb symptoms
at an earlier stage in the lives of these individuals.

Currently, the most commonly used medication is
anti-epileptic drugs (AEDs). For individuals who
have milder seizures, only one AED is prescribed. In
other words a monotherapy strategy is used. For
individuals who have other complications or more
severe forms of seizures, a polytherapy approach is
used where two or more AEDs are used in
combination. AEDs, however, come with many side
effects. For example, AEDs used in monotherapy or
polytherapy can reduce vitamin D levels thereby
increasing that individual’s risk for fractures.
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